Frovatriptan (trade name Frova) is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.
Frovatriptan has mean terminal elimination half-life of approximately 26 hours, which is substantially longer than other triptans.
Pharmacokinetics of Two 6-Day Frovatriptan Dosing Regimens Used for the Short-Term Prevention of Menstrual Migraine: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover, Single-Centre Study in Healthy Female Volunteers
May 01, 2009; Abstract Objective: This study aimed to assess the pharmacokinetics and tolerability of once- and twice-daily Frovatriptan...